Review on intermediate filaments of the nervous system and their pathological alterations
暂无分享,去创建一个
[1] Jeffrey A. Cohen,et al. Neurofilament mRNA is reduced in Parkinson's disease substantia nigra pars compacta neurons , 1993, The Journal of comparative neurology.
[2] F. Dasí,et al. Loss of heterozygosity at 1p-19q induces a global change in oligodendroglial tumor gene expression , 2009, Journal of Neuro-Oncology.
[3] Webster K. Cavenee,et al. Erratum: The 2007 WHO classification of tumours of the central nervous system (Acta Neuropathol (2007) vol. 114 (97-109)) , 2007 .
[4] J. Julien,et al. Normal role of the low‐molecular‐weight neurofilament protein in mitochondrial dynamics and disruption in Charcot‐Marie‐Tooth disease , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[5] R. Hoffman. Nestin-driven green fluorescent protein as an imaging marker for nascent blood vessels in mouse models of cancer. , 2011, Methods in molecular biology.
[6] E. Lane,et al. The Human Intermediate Filament Database: comprehensive information on a gene family involved in many human diseases , 2008, Human mutation.
[7] C. Bettegowda,et al. Pre- and post-operative plasma glial fibrillary acidic protein levels in patients with newly diagnosed gliomas , 2012, Journal of Neuro-Oncology.
[8] I. Pommepuy,et al. Alpha-internexin expression in gliomas: relationship with histological type and 1p, 19q, 10p and 10q status , 2011, Journal of Clinical Pathology.
[9] G. Gabbiani,et al. Intermediate filament protein synemin is present in human reactive and malignant astrocytes and associates with ruffled membranes in astrocytoma cells , 2005, Glia.
[10] R A Crowther,et al. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[11] H. Armah. Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile , 2010 .
[12] R. Perrot,et al. Neuronal intermediate filaments and neurodegenerative disorders , 2009, Brain Research Bulletin.
[13] L. Rosengren,et al. Serum levels of glial fibrillary acidic protein correlate to tumour volume of high‐grade gliomas , 2007, Acta neurologica Scandinavica.
[14] D. Řípová,et al. Patients with Alzheimer disease have elevated intrathecal synthesis of antibodies against tau protein and heavy neurofilament , 2012, Journal of Neuroimmunology.
[15] R. Liem. Neuronal intermediate filaments. , 1990, Current opinion in cell biology.
[16] B. Helfand,et al. Rapid transport of neural intermediate filament protein , 2003, Journal of Cell Science.
[17] B. Bergamasco,et al. Proteome analysis of human substantia nigra in Parkinson's disease , 2004, Proteomics.
[18] Haibo Chen,et al. Correlational study of the serum levels of the glial fibrillary acidic protein and neurofilament proteins in Parkinson's disease patients , 2012, Clinical Neurology and Neurosurgery.
[19] A. Hays,et al. Peripherin and Neurofilament Protein Coexist in Spinal Spheroids of Motor Neuron Disease , 1992, Journal of neuropathology and experimental neurology.
[20] M. Strong,et al. Quantitative phosphoproteomic analysis of neuronal intermediate filament proteins (NF‐M/H) in Alzheimer's disease by iTRAQ , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[21] K. Hoang-Xuan,et al. α-Internexin expression identifies 1p19q codeleted gliomas , 2009, Neurology.
[22] W G Alvord,et al. Familial Amyotrophic Lateral Sclerosis, 1850-1989: A Statistical Analysis of the World Literature , 1991, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[23] L. Rosengren,et al. Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS , 2003, Neurology.
[24] H. Steinmetz,et al. Serum GFAP is a diagnostic marker for glioblastoma multiforme. , 2007, Brain : a journal of neurology.
[25] R. Bjerkvig,et al. DNA repair and cancer stem-like cells--potential partners in glioma drug resistance? , 2008, Cancer treatment reviews.
[26] G. Perry,et al. Phosphorylation of Neurofilaments Is Altered in Amyotrophic Lateral Sclerosis , 1988, Journal of neuropathology and experimental neurology.
[27] O. Kalita,et al. Analysis of VEGF, Flt-1, Flk-1, nestin and MMP-9 in relation to astrocytoma pathogenesis and progression. , 2009, Neoplasma.
[28] 勇人 伊古田. Systematic immunohistochemical profiling of 378 brain tumors with 37 antibodies using tissue microarray technology , 2007 .
[29] J. Julien,et al. Normal dendritic arborization in spinal motoneurons requires neurofilament subunit L , 2002, The Journal of comparative neurology.
[30] Arie Perry,et al. Clinicopathologic aspects of 1p/19q loss and the diagnosis of oligodendroglioma. , 2007, Archives of pathology & laboratory medicine.
[31] D. Rodriguez,et al. Mutations in GFAP, encoding glial fibrillary acidic protein, are associated with Alexander disease , 2001, Nature Genetics.
[32] S. Züchner,et al. Mechanisms of Disease: a molecular genetic update on hereditary axonal neuropathies , 2006, Nature Clinical Practice Neurology.
[33] Kimberly L. Walker,et al. Loss of Neurofilaments Alters Axonal Growth Dynamics , 2001, The Journal of Neuroscience.
[34] T. Matsushige,et al. Serum neurofilament concentrations in children with prolonged febrile seizures , 2012, Journal of the Neurological Sciences.
[35] N. Hashimoto,et al. Gene Expression-Based Molecular Diagnostic System for Malignant Gliomas Is Superior to Histological Diagnosis , 2007, Clinical Cancer Research.
[36] R. Lindberg,et al. Neurofilament heavy chain and heat shock protein 70 as markers of seizure‐related brain injury , 2012, Epilepsia.
[37] H. Wiśniewski,et al. An Antigenic Profile of Lewy Bodies: Immunocytochemical Indication for Protein Phosphorylation and Ubiquitination , 1989, Journal of neuropathology and experimental neurology.
[38] A. Messing,et al. GFAP expression as an indicator of disease severity in mouse models of Alexander disease , 2013, ASN neuro.
[39] E. Shaw,et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. , 2006, Cancer research.
[40] J. Kassubek,et al. Neurofilament heavy‐chain NfHSMI35 in cerebrospinal fluid supports the differential diagnosis of Parkinsonian syndromes , 2006, Movement disorders : official journal of the Movement Disorder Society.
[41] Y. Kim,et al. Degeneration and transdifferentiation of human lens epithelial cells in nuclear and anterior polar cataracts. , 1999, Journal of cataract and refractive surgery.
[42] I. Nakano,et al. Brain Tumor Stem Cells , 2006, Pediatric Research.
[43] J. Schiefer,et al. Neurofilament light chain as an early and sensitive predictor of long-term neurological outcome in patients after cardiac arrest. , 2013, International journal of cardiology.
[44] C. Polman,et al. Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study , 2005, Journal of Neurology, Neurosurgery & Psychiatry.
[45] J. Žůrek,et al. Hyperphosphorylated neurofilament NF-H as a predictor of mortality after brain injury in children , 2011, Brain injury.
[46] M. Perng,et al. Alexander disease causing mutations in the C-terminal domain of GFAP are deleterious both to assembly and network formation with the potential to both activate caspase 3 and decrease cell viability. , 2011, Experimental cell research.
[47] P. Janmey,et al. Bidirectional translocation of neurofilaments along microtubules mediated in part by dynein/dynactin. , 2000, Molecular biology of the cell.
[48] A. Ludolph,et al. Axonal damage markers in cerebrospinal fluid are increased in ALS , 2006, Neurology.
[49] H. Zetterberg,et al. Light subunit of neurofilament triplet protein in the cerebrospinal fluid after subthalamic nucleus stimulation for Parkinson’s disease , 2011, Acta neurologica Scandinavica.
[50] C. Wikkelsø,et al. Patients with Amyotrophic Lateral Sclerosis and Other Neurodegenerative Diseases Have Increased Levels of Neurofilament Protein in CSF , 1996, Journal of neurochemistry.
[51] M. Faiz,et al. Synemin is expressed in reactive astrocytes and Rosenthal fibers in Alexander disease , 2014, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[52] W. F. Abdo,et al. CSF neurofilament light chain and tau differentiate multiple system atrophy from Parkinson's disease , 2007, Neurobiology of Aging.
[53] S. Beck,et al. Cell surface Nestin is a biomarker for glioma stem cells. , 2013, Biochemical and biophysical research communications.
[54] Gerry Shaw,et al. Phosphorylated neurofilament heavy subunit (pNF-H) in peripheral blood and CSF as a potential prognostic biomarker in amyotrophic lateral sclerosis , 2012, Journal of Neurology, Neurosurgery & Psychiatry.
[55] O. Skalli,et al. Intermediate filament protein synemin contributes to the migratory properties of astrocytoma cells by influencing the dynamics of the actin cytoskeleton , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[56] P. Mulvihill,et al. Filaments of Lewy bodies contain insoluble cytoskeletal elements. , 1992, The American journal of pathology.
[57] O. Evgrafov,et al. A new variant of Charcot-Marie-Tooth disease type 2 is probably the result of a mutation in the neurofilament-light gene. , 2000, American journal of human genetics.
[58] R. Liem,et al. Mutations in the neurofilament light gene linked to Charcot‐Marie‐Tooth disease cause defects in transport , 2005, Journal of neurochemistry.
[59] A. Orr,et al. Synemin promotes AKT-dependent glioblastoma cell proliferation by antagonizing PP2A , 2012, Molecular biology of the cell.
[60] Meng Yang,et al. Nestin-linked green fluorescent protein transgenic nude mouse for imaging human tumor angiogenesis. , 2005, Cancer research.
[61] L. Rosengren,et al. Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis , 2010, Journal of Neurology.
[62] E. Dahl,et al. Intermediate filament dynamics and breast cancer: Aberrant promoter methylation of the Synemin gene is associated with early tumor relapse , 2010, Oncogene.
[63] R. Crowther,et al. α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies , 1998 .
[64] P. Wong,et al. Pathogenesis of two axonopathies does not require axonal neurofilaments , 1998, Nature.
[65] K. Blennow,et al. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. , 2012, Archives of neurology.
[66] M. Reilly. NEFL‐related Charcot–Marie–Tooth disease: An unraveling story , 2009, Annals of neurology.
[67] M. Mann,et al. Integrated analysis of the cerebrospinal fluid peptidome and proteome. , 2008, Journal of proteome research.
[68] G. Giovannoni,et al. A specific ELISA for measuring neurofilament heavy chain phosphoforms. , 2003, Journal of immunological methods.
[69] A. Peterson,et al. Neurofilament-deficient axons and perikaryal aggregates in viable transgenic mice expressing a neurofilament-β-galactosidase fusion protein , 1994, Neuron.
[70] M N Rossor,et al. A Systematic Review and Meta-Analysis of CSF Neurofilament Protein Levels as Biomarkers in Dementia , 2007, Neurodegenerative Diseases.
[71] H. Ishikawa,et al. MITOSIS AND INTERMEDIATE-SIZED FILAMENTS IN DEVELOPING SKELETAL MUSCLE , 1968, The Journal of cell biology.
[72] G. Logroscino,et al. Elevated cerebrospinal fluid neurofilament light levels in patients with amyotrophic lateral sclerosis: a possible marker of disease severity and progression , 2012, European journal of neurology.
[73] V. Tung,et al. Antagonistic Roles of Neurofilament Subunits NF-H and NF-M Against NF-L in Shaping Dendritic Arborization in Spinal Motor Neurons , 1998, The Journal of cell biology.
[74] John Hardy,et al. A Hundred Years of Alzheimer's Disease Research , 2006, Neuron.
[75] Zhigang Xie. Brain Tumor Stem Cells , 2009, Neurochemical Research.
[76] H. Wiśniewski,et al. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[77] L. Rosengren,et al. Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis , 1998, Journal of neurology, neurosurgery, and psychiatry.
[78] D. Nam,et al. Identification of a peptide that interacts with Nestin protein expressed in brain cancer stem cells. , 2011, Biomaterials.
[79] Tomokatsu Yoshida,et al. Clinical aspects and pathology of Alexander disease, and morphological and functional alteration of astrocytes induced by GFAP mutation , 2012, Neuropathology : official journal of the Japanese Society of Neuropathology.
[80] Gerry Shaw,et al. Hyperphosphorylated neurofilament NF-H is a serum biomarker of axonal injury. , 2005, Biochemical and biophysical research communications.
[81] C. Shaw,et al. Charcot-Marie-Tooth disease neurofilament mutations disrupt neurofilament assembly and axonal transport. , 2002, Human molecular genetics.
[82] F. Caire,et al. 1p19q LOH patterns and expression of p53 and Olig2 in gliomas: relation with histological types and prognosis , 2010, Modern Pathology.
[83] S. Bhattacharya,et al. Dominant cataract formation in association with a vimentin assembly disrupting mutation. , 2009, Human molecular genetics.
[84] B. Kalmar,et al. Plasma Neurofilament Heavy Chain Levels Correlate to Markers of Late Stage Disease Progression and Treatment Response in SOD1G93A Mice that Model ALS , 2012, PloS one.
[85] P. Cochard,et al. Initial expression of neurofilaments and vimentin in the central and peripheral nervous system of the mouse embryo in vivo , 1984, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[86] Santosh Kesari,et al. Malignant gliomas in adults. , 2008, The New England journal of medicine.
[87] M. Sharief,et al. Heightened intrathecal release of axonal cytoskeletal proteins in multiple sclerosis is associated with progressive disease and clinical disability , 2002, Journal of Neuroimmunology.
[88] R. McKay,et al. CNS stem cells express a new class of intermediate filament protein , 1990, Cell.
[89] K. Aldape,et al. Anaplastic Oligodendroglial Tumors: Refining the Correlation among Histopathology, 1p 19q Deletion and Clinical Outcome in Intergroup Radiation Therapy Oncology Group Trial 9402 , 2008, Brain pathology.
[90] I. Grundke‐Iqbal,et al. Hyperphosphorylation and accumulation of neurofilament proteins in Alzheimer disease brain and in okadaic acid‐treated SY5Y cells , 2001, FEBS letters.
[91] B. Scheithauer,et al. The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.
[92] V. Meininger,et al. A Frameshift Deletion in Peripherin Gene Associated with Amyotrophic Lateral Sclerosis* , 2004, Journal of Biological Chemistry.
[93] V. Meininger,et al. Variants of the heavy neurofilament subunit are associated with the development of amyotrophic lateral sclerosis. , 1994, Human molecular genetics.
[94] T B Shea,et al. Kinesin-mediated transport of neurofilament protein oligomers in growing axons. , 1999, Journal of cell science.
[95] R. Nixon,et al. Dynamics of neuronal intermediate filaments: a developmental perspective. , 1992, Cell motility and the cytoskeleton.
[96] E. Perry,et al. Neurogenic abnormalities in Alzheimer's disease differ between stages of neurogenesis and are partly related to cholinergic pathology , 2012, Neurobiology of Disease.
[97] M. Omary,et al. Intermediate filament proteins and their associated diseases. , 2004, The New England journal of medicine.
[98] I. Grundke‐Iqbal,et al. Regulation between O‐GlcNAcylation and phosphorylation of neurofilament‐M and their dysregulation in Alzheimer disease , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[99] Yoav Ben-Shlomo,et al. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. , 2002, Brain : a journal of neurology.
[100] K. Hoang-Xuan,et al. Diagnostic and prognostic value of alpha internexin expression in a series of 409 gliomas. , 2011, European journal of cancer.
[101] Y. Itoyama,et al. Marked increase in cerebrospinal fluid glial fibrillar acidic protein in neuromyelitis optica: an astrocytic damage marker , 2009, Journal of Neurology, Neurosurgery, and Psychiatry.